ABSTRACT a-Conotoxins, as nicotinic acetylcholine receptor (nAChR) antagonists, are powerful tools for dissecting biologic processes and guiding drug development. The a3b2 and a3b4 nAChR subtypes are expressed in the central and peripheral nervous systems and play a critical role in various pathophysiological conditions ranging from nicotine addiction to the development and progression of lung cancer. Here we used the a4/7-conotoxin RegIIA, a disulfidebonded peptide from the venom of Conus regius, and its analog [N11A,N12A]RegIIA to probe the specific pharmacological properties of rat and human nAChR subtypes. nAChR subtypes were heterologously expressed in Xenopus oocytes and two-electrode voltage clamp recordings used to investigate the effects of the peptides on nAChR activity. RegIIA potently inhibited currents evoked by acetylcholine (ACh) at rat a3b2 (IC 50 5 10.7 nM), whereas a 70-fold lower potency was observed at human a3b2 nAChR (IC 50 5 704.1 nM). Conversely, there were no speciesspecific differences in sensitivity to RegIIA at the a3b4 nAChR. Receptor mutagenesis and molecular dynamics studies revealed that this difference can be attributed primarily to a single amino acid change: Glu198 on the rat a3 subunit corresponding to a proline on the human subunit. These findings reveal a novel species-and subunit-specific receptor-antagonist interaction.
Introduction
Neuronal nicotinic acetylcholine receptors (nAChR) are pentameric transmembrane proteins forming ligand-gated ion channels that are sensitive to nicotine and endogenously activated by acetylcholine (ACh). Most neuronal nAChR subtypes form heteropentamers of a2-6 and b2-4 subunits combined in different stoichiometries (Millar and Gotti, 2009 ). Neuronal nAChRs are important components of synaptic transmission and are expressed pre-and postsynaptically in the peripheral nervous system, and in cholinergic neurons throughout the brain (Jensen et al., 2005) . They regulate the release of several neurotransmitters and are functionally involved in various cognitive roles, such as learning, memory, and motor control (Jensen et al., 2005) . Not surprisingly, neuronal nAChR activity is also involved in a wide range of disease states. For example, the a3b4 nAChR is implicated in tobacco addiction, drug abuse, and lung cancer (Jensen et al., 2005; Hurst et al., 2013) , making this particular nAChR subtype an interesting target for novel therapeutics. Similarly the a3b2 nAChR subtype is expressed in specific areas of the central and peripheral nervous systems, including the medial habenula, cerebellum, spinal cord, retina, and autonomic ganglia (Millar and Gotti, 2009; Hurst et al., 2013) . However, owing to a lack of subtype-selective tools, our knowledge of the exact roles of individual nAChR subtypes in pathophysiological states is limited. This in turn severely limits the ability to fully exploit nAChR pharmacology for potential pharmaceutical applications, evidenced by a number of drugs failing in late-state clinical trials (Decker et al., 2008) .
a-Conotoxins are short disulfide-bonded peptides (12-20 amino acid residues) isolated from the venom of marine snails of the Conus genus. a-Conotoxins are classified as selective antagonists of muscle and neuronal nAChRs and are promising pharmacological probes and potential therapeutics (Olivera et al., 2008; Muttenthaler et al., 2011; Lebbe et al., 2014) . a4/7-Conotoxin RegIIA, isolated from the venom of Conus regius, has previously been characterized as a potent inhibitor of rat a3b2, a3b4, and human a7 nAChRs at nanomolar concentrations (Franco et al., 2012) . Furthermore, a recent study using alanine-scanning mutagenesis identified a novel [N11A,N12A] RegIIA analog that selectively targets the rat a3b4 nAChR subtype (Kompella et al., 2015) . Recent literature suggests a-conotoxins not only have a characteristic activity profile for different nAChR subtypes, but also exhibit selective activity on subtypes of different species (Azam and McIntosh, 2012; Yu et al., 2013) . Species differences could result in discrepancies during preclinical testing that guides clinical trials and are therefore of pharmaceutical significance.
Here, we report the novel species-and subunit-specific pharmacology exhibited by a-conotoxin RegIIA at a3b2 and a3b4 nAChR subtypes. Using receptor mutagenesis and molecular dynamic simulations, we identify the key interactions involved in differential RegIIA activity at these receptors.
Materials and Methods
Peptide Synthesis. a-Conotoxins RegIIA and [N11A,N12A] RegIIA were synthesized as described previously (Kompella et al., 2015) and obtained from Dr. Richard J. Clark, University of Queensland, Australia.
Protein Sequence Alignment. Protein sequences of rat and human a3 (RefSeq accession numbers NP_434692 and NP_000734, respectively) and b2 nAChR subunits (RefSeq accession numbers NP_062170 and NP_000739, respectively) were aligned using CLC Viewer 7 software (CLC bio, Aarhus, Denmark). Residues were numbered according to the sequences of the mature proteins.
Site-Directed Mutagenesis of a3 and b2 nAChR Subunits. Plasmid DNAs encoding human a3, b2 and b4 nAChR subunits were obtained from OriGene Technologies Inc. (Rockville, MD) and the fulllength cDNAs were subcloned into the pT7TS Xenopus expression vector (Addgene plasmid 17091). Rat a3, b2 and b4 nAChR cDNA clones described previously (Franco et al., 2012) were also subcloned into pT7TS. Individual amino acids in the N-terminal extracellular domain (ECD) that precedes transmembrane segment I of rat a3 and b2 nAChRs were mutated to the corresponding human residues using the Geneart Site-Directed Mutagenesis System (Invitrogen, Carlsbad, CA). Rat a3 nAChR constructs generated were ra3 Electrophysiological Recordings in Xenopus Oocytes. RNA preparation, Xenopus laevis oocyte preparation, and expression of nAChR subunits in oocytes were performed as described previously (Hogg et al., 2003) . Briefly, plasmids were linearized with appropriate restriction enzymes, and cRNA synthesized in vitro with the T7 mMessage mMachine Kit (Ambion, Foster City, CA). Oocytes were injected with 5 ng of cRNA, and then kept at 18°C in sterile ND96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, at pH 7.4) supplemented with 50 mg/l gentamycin and 100 mg/IU per milliliter penicillin/streptomycin for 2-5 days before recording.
Membrane currents from Xenopus oocytes were recorded using a single-channel two-electrode voltage clamp setup (virtual ground circuit) with a GeneClamp 500B amplifier (Molecular Devices, Sunnyvale, CA). Voltage-recording and current-injecting electrodes were pulled from borosilicate glass (GC150T-7.5; Harvard Apparatus Ltd., Holliston, MA) and had resistances of 0.3-1.5 MV when filled with 3 M KCl. All recordings were made at room temperature (21-23°C) using a bath solution of ND96 as described above, and oocytes were voltage-clamped at a holding potential of -80 mV. During recordings, the oocytes were perfused continuously at a rate of 2 ml/min including application of ACh (50 mM) for 2 seconds and 180-240-second washout periods between applications. Oocytes were incubated with the peptide for 300 seconds before perfusion with ACh plus peptide. Data were sampled at 500 Hz and filtered at 100 Hz.
Peak ACh-evoked current amplitude was recorded using pClamp 9 software (Molecular Devices). The effects of peptide on ACh-evoked currents were defined as peak current amplitudes relative to the average peak current amplitude of 3-5 control ACh applications recorded before preincubation with the peptides. Concentration-response curves were fitted by unweighted nonlinear regression to the logistic equation
where E x is the response, X is the antagonist concentration, E max is the maximal response, n H is the Hill coefficient, and IC 50 is the antagonist concentration that gives 50% inhibition of the agonist response. All electrophysiological data were pooled (n 5 4-8 for each data point) and represent arithmetic means 6 standard error of the fit. Curves were fitted and statistics calculated using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA). Homology Modeling. Homology models were generated using Modeler9v6 (Sali and Blundell, 1993) . Homology models of the ECD of rat and human (a3) (Hansen et al., 2005) .
Molecular Dynamics Simulations. Each receptor complex was placed in a separate cubic simulation box with edge length 100 Â 100 Â 100 Å and solvated with TIP3P water molecules. Na 1 and Cl 2 were added to neutralize charge and maintain an ionic concentration of ∼150 mM. All simulations were performed using GROMACS version 4.6.3 (Science for Life Laboratory, Stockholm, Sweden; Lindahl et al., 2001; Van Der Spoel et al., 2005) with the CHARMM27 force-field version 2.0 (with cmap) (Bjelkmar et al., 2010) . The complexes were energy-minimized using the steepest descent algorithm and an energy gradient convergence criterion of 0.01 kcal/mol per angstrom. All molecular dynamics (MD) simulations were performed using constant particle number, pressure, and temperature (NPT) ensemble, with temperature maintained at 300 K using the v-rescale temperature coupling algorithm (Bussi et al., 2007) , and pressure maintained at 1 bar using the Parrinello-Rahman pressure coupling algorithm (Parrinello and Rahman, 1981) . Time steps of 2 femtoseconds were used to integrate all simulations. Ten independent simulations were performed for each complex using different random seeds to assign initial particle velocities. Each simulation was performed for 20 nanoseconds. Molecular graphics were produced using VMD version 1.9.2 (http://www.ks.uiuc.edu/; Humphrey et al., 1996) . Molecular Mechanics-Poisson-Boltzmann Surface-Area Calculations. The binding free energies (DG bind ) of RegIIA to rat and human (a3) 2 (b2) 3 , and rat (a3[Q198P]) 2 (b2) 3 , were calculated using the molecular mechanics-Poisson-Boltzmann surface-area (MM-PBSA) method implemented in the GROMACS tools g_mmpbsa (Kumari et al., 2014) and APBS (Dolinsky et al., 2004 (Dolinsky et al., , 2007 . The binding free energy is defined as DG bind 5 G complex -G free-protein -G free-ligand . In the MM-PBSA approach, the free energy G is given by G 5 E gas 1 G PB 1 gΑ 1 b 2 TS, where E gas is the gas-phase molecular mechanics potential energy defined by the force field employed, G PB is the polar contribution to the solvation free energy calculated using the Poisson-Boltzmann equation, A is the solvent-accessible surface area, g and b are empirical parameters, and TS is the entropy term. In the present calculations, the change in entropy is assumed to be negligible. The APBS software package was employed for numerical solution of the linear Poisson-Boltzmann equation. A grid spacing of 0.5 Å was used for the fine cubic lattice. The CHARMM radii and charges were used to generate the PQR files. The continuum medium is assumed to have a dielectric constant of 80.00, and the solute was assigned a dielectric constant of 2. The two empirical parameters were set with g 5 0.0226778 kJ/(mol×Å 2 ) and b 5 0. The surface area A was estimated using a probe radius of 1.4 Å. The DG bind was decomposed into individual receptor and toxin residue contributions using g_mmpbsa. For each RegIIA-nAChR complex, DG bind values were calculated for 100 frames from each of 10 independent MD simulations. Uncertainties are reported as S.E.M. over 10 independent simulations and two a3 (1) Results a-Conotoxin RegIIA Exhibits Differential Selectivity at the Rat and Human a3b2 but Not a3b4 nAChR Subtypes. RegIIA has been shown to selectively inhibit ra3b2, ra3b4 and ha7 nAChR subtypes (Franco et al., 2012) . To examine if RegIIA exhibits species-specific activity differences, inhibition of ACh-evoked currents at human nAChR subtypes expressed in Xenopus oocytes was investigated. Surprisingly, an initial screening with 100 nM RegIIA at ha3b2 demonstrated only minor (∼12%) reduction of AChevoked current amplitude, whereas the same concentration almost completely blocked the homologous rat a3b2 nAChR subtype ( Fig. 1A) (Franco et al., 2012) . However, at rat and human a3b4 nAChR subtypes, 100 nM RegIIA exhibited similar inhibitory effects on ACh-evoked currents (Fig. 1A) . Concentration-response curves for RegIIA inhibition of ha3b2 showed a significant shift to the right relative to that of the homologous rat receptor, whereas RegIIA activity at rat and human a3b4 receptors showed no distinguishable change (Fig. 1B) . IC 50 values calculated from the concentrationresponse curves revealed an approximately 70-fold difference in RegIIA activity with an IC 50 of 704.1 nM (95% CI 502.9 -985.9; n H 5 1.2) at the human a3b2 subtype compared with 10.7 nM (95% CI 8.8 -12.9; n H 5 1.1) at rat a3b2 subtype (Table 1) . This change was even more prominent for the RegIIA analog [N11A,N12A]RegIIA, which was inactive at the ha3b2 subtype at 100 mM while retaining micromolar potency at ra3b2 (IC 50 of 9.9 mM, 95% CI 7.9 -12.4 nM; n H 5 1.5) (Fig.  1C) . In contrast, [N11A,N12A]RegIIA was almost equipotent at ha3b4 and ra3b4 nAChR subtypes (IC 50 of 259.4 nM, 95% CI 224.4 -299.9 nM; n H 5 1.8, and 369.6 nM, 95% CI 308.9 -442.3 nM; n H 5 1.7, respectively) (Fig. 1C) .
The Nonhomologous Residue Q198 of the Rat a3 Subunit Is a Key Determinant of Species-Specific Differences in a-Conotoxin RegIIA Potency at the a3b2 nAChR. To examine possible structural features that determine species-specific differences in sensitivity to RegIIA, rat and human a3 and b2 subunit N-terminal ECD protein sequences were compared. Pairwise alignments of mature protein sequences lacking the signal peptide revealed a number of nonconserved residues (Fig. 2, A and B) . The ECD of the b2 subunit is highly homologous between the two species, differing in only three amino acid residues (98.6% homology). In the rat sequence, these are D73 (E in human), D165 (E in human) and I181 (V in human) (Fig. 2B ). All three sites represent conservative amino acid substitutions. The a3 subunit exhibits eleven nonconserved residues in the ECD of the mature proteins ( Fig. 2A) . However, only three nonhomologous residues were identified within the ACh-binding loops that correspond to the previously identified and homologous loops of the a7 subunit (Corringer et al., 2000) . These are rat a3 E187 (D in human) and Concentration-response curves for RegIIA inhibition of rat and human a3b2 and a3b4 nAChRs reveal RegIIA is approximately 70-fold less potent at human compared with rat a3b2 nAChR. RegIIA is equipotent at a3b4 nAChRs of both species. The IC 50 , 95% CI and Hill slope (n H ) values obtained from the concentration-response curves are shown in Table 1 . (C) Concentration-response curves for the synthetic analog [N11A,N12A]RegIIA show no activity at human a3b2 compared with micromolar potency at the rat homolog. No species-specific differences in potency were observed at a3b4 nAChR. Data represent mean 6 S.E.M., n = 3-6.
Species Difference of a-Conotoxin RegIIA Potency at nAChRs Q198 (P in human) located within loop C and rat b2 D165 (E in human) within loop F.
To evaluate the contribution of each nonhomologous amino acid to the observed ∼70-fold difference in RegIIA activity, we carried out site-directed mutagenesis of rat a3 and b2 residues to the human counterparts (denoted by boxes in Fig. 2, A and B). When tested for sensitivity to RegIIA, all mutations, except for rat a3[Q198P]b2, caused only modest, 3-to 4-fold, changes in IC 50 (Fig. 2D, Table 1 ). In contrast, exchange of the single residue Q198 to P was sufficient to shift the RegIIA concentrationresponse curve 50-fold; from an IC 50 of 10.7 nM (95% CI 8.8 -12.9; n H 5 1.1) in wild-type ra3b2 to an IC 50 of 520.9 nM (95% CI 400.2 -678.1; n H 5 0.8) in ra3[Q198P]b2. The latter value was similar to the IC 50 obtained with ha3b2 (Fig. 2C, Table 1 ). The opposite human a3 receptor subunit mutant ha3[P198Q]b2, expressed in oocytes, exhibited substantially reduced sensitivity to ACh compared with the wild-type (.1000-fold), and therefore the activity of RegIIA could not be evaluated. However, when ha3[P198Q] was coexpressed with rat b2, the hybrid ha3[P198Q]rb2 receptor produced robust ACh-evoked currents. The concentration-response curve for inhibition of ha3[P198Q]rb2 by RegIIA was shifted to the left compared with ha3b2, exhibiting an IC 50 concentration of 31.0 nM (95% CI 25.0 -38.4; n H 5 1.8) (Fig. 2C, Table 1 ). Taken together these findings revealed P198 in human a3 as a critical determinant for the reduced potency of RegIIA at ha3b2 compared with the homologous rat nAChR subtype.
MD Simulations and Free Energy Calculations Reveal the Molecular Mechanisms by Which Human a3 P198 Governs Loss of Sensitivity to a-Conotoxin RegIIA. We performed all-atom MD simulations of the ECDs of rat wild-type, rat a3[Q198P]b2 and human a3b2 receptors complexed with RegIIA. To understand the molecular basis for lack of low-nanomolar inhibition at ra3[Q198]b2 and ha3b2 receptors by RegIIA (hereafter termed "RegIIA-inactive" subtypes), we employed MM-PBSA calculations on the MD simulation trajectories to estimate the absolute DG bind of RegIIA to each of the receptors. These values were then used to estimate the (D)DG bind of RegIIA to a3[Q198P]b2 and human a3b2, relative to rat a3b2 (Fig. 3A) . Both ra3[Q198P]b2 and ha3b2 exhibited positive (D)DG bind values of 15.0 6 2.5 kJ/mol (p 5 0.07) and 1 9.3 6 2.5 kJ/mol (p , 0.05), respectively. These calculated values indicated that, compared with ra3b2, there is moderate evidence for lower RegIIA binding to ra3[Q198P]b2, and statistically significant lower RegIIA binding to ha3b2. These findings are in qualitative agreement with the experimental oocyte recording data.
We next aimed to identify the RegIIA and a3b2 residues that make the most significant contribution to the loss in RegIIA affinity at a3[Q198P]b2 and human a3b2. We used the g_mmpbsa script (Kumari et al., 2014) to decompose DG bind into individual contributions from RegIIA and nAChR. A (D)DG bind value for each residue was then calculated by subtracting the (per-residue) DG bind of rat a3b2 from those of the RegIIA-inactive subtypes. Inspection of (D)DG bind values for each RegIIA moiety interacting at a3[Q198P]b2 or ha3b2 revealed a number of residues with a significantly positive (D)DG bind for both RegIIA-inactive a3b2 subtypes (marked with asterisks in Fig. 3B , p , 0.05). Of particular interest are RegIIA-N11 (13.5 6 0.2 kJ/mol at a3[Q198P]b2 and 14.6 6 0.2 kJ/mol at ha3b2) and RegIIA-N12 (12.2 6 0.2 kJ/mol at a3[Q198P]b2 and 12.3 6 0.2 kJ/mol at ha3b2). Both N11 and N12 are in close proximity to a3-E195 in loop C (three residues away from the key residue a3-Q198). a3-E195 also exhibits positive (D)DG bind values for both ra3[Q198P]b2 and ha3b2 (18.8 6 1.0 kJ/mol and 110.0 6 2.0 kJ/mol, respectively, p , 0.05) (Fig. 4A) . Moreover, for both ra3b4 and ha3b4, a3-E195 also exhibits positive (D)DG bind relative to ra3b2; however, they are much lower than for the RegIIAinactive subtypes discussed above (12.2 6 1.0 and 2.6 6 1.0 kJ/mol, respectively), and neither are significantly different from that of ra3b2. The statistically significant positive (D)DG bind contributions of RegIIA-N11/N12, together with that of a3-E195 for ha3b2 and a3[Q198P]b2, but not for ha3b4 and ra3b4, suggests the interactions between these residues play a key role in differentiating RegIIA activity at the RegIIA-active rat a3b2 and a3b4 subtypes compared with the two RegIIAinactive receptors in this study.
Additionally, we identified that b2-S168 at the complementary face exhibits marginally positive, though statistically significant, (D)DG bind values for both ra3[Q198P]b2 (11.0 6 0.2 kJ/mol) and ha3b2 (12.0 6 0.2 kJ/mol) (p , 0.05) (Fig. 4D) . At all a3b2 receptors studied, b2-S168 is in occasional contact with RegIIA-S4. We note that S4 also exhibits statistically significant positive (D)DG bind values at ra3[Q198P]b2 and ha3b2 (12.2 6 0.2 and 13.5 6 0.2 kJ/mol, respectively, p , 0.05). This may be partly attributable to the marginally more stable H-bond between S4 and b2-S168 at ra3b2 (not shown). Interestingly, for ra3b2, b2-S168 forms a hydrogen bond with neighboring b2-D171. This, in turn, forms a persistent salt bridge with the N-terminal amine of RegIIA-G1. Inspection of the (D)DG bind values for RegIIA (Fig. 3B ) reveals a significant (D)DG bind contribution by RegIIA-G1 at ha3b2 (13.9 6 0.6 kJ/mol, p , 0.05). However, there was no significant (D)DG bind contribution at a3[Q198P]b2 (p ∼1.0). These results suggest both principal and complementary subunits contribute to species differences in RegIIA activity at human and rat a3b2. However, it is mainly the principal face that confers selectivity between wild-type ra3b2 and ra3[Q198P]b2. Discussion a-Conotoxins are valuable pharmacological tools for studying nAChR function because they exhibit different specificities Data from previous report (Kompella et al., 2015) .
for different receptor subtypes (Terlau and Olivera, 2004; Muttenthaler et al., 2011; Lebbe et al., 2014) . They are also promising lead compounds for drugs that target pathophysiological conditions related to nAChRs, such as chronic pain, cancers, and addiction (Olivera et al., 2008; Brady et al., 2013; Schroeder et al., 2013) . However, most a-conotoxins have only been characterized at heterologously expressed receptors in one species, usually rat, in expression systems such as Xenopus oocytes. Evaluating a-conotoxin activity at human nAChR subtypes is crucial for our understanding of human nAChR pharmacology and to the development of new, selective and potent pharmacological probes.
Evidence that a-conotoxins can exhibit considerably different potencies on homologous nAChR subtypes of different species comes from a few recent reports (Azam and McIntosh, 2012; Yu et al., 2013; Azam et al., 2015) . Here, we report novel species-and receptor subtype-specific differences between a3b2 and a3b4 nAChR sensitivity to a-conotoxin RegIIA. RegIIA, previously characterized as a competitive antagonist of rat a3b2 nAChR with an IC 50 of 10.7 nM (Kompella et al., Fig. 2 . The nonhomologous residue at position 198 (Q in rat, P in human) of the a3 subunit is responsible for the species differences in potency of a-conotoxin RegIIA. (A, B) Sequence alignments of the N-terminal ECDs of rat and human a3 nAChR subunits (A) and b2 nAChR subunits (B) reveal species-specific differences in amino acid sequences. Residues that differ between the two species are highlighted in bold and conserved residues are indicated with dots. Residues that were mutated for testing in this study are framed. Bars indicate the ACh binding domain loops A, B, and C of the principal interface, and loops D, E, and F of the complementary interface, respectively (see Shiembob et al., 2006) Table 1 . All data points represent mean 6 S.E.M., n = 3-6, ***p , 0.001.
Species Difference of a-Conotoxin RegIIA Potency at nAChRs 2015), is 70-fold less potent at the homologous human a3b2 subtype (IC 50 of 704 nM). Interestingly, human and rat a3b4 nAChR subtypes have the same sensitivity to RegIIA.
The potency difference observed at a3b2 but not a3b4 subtypes suggests that only a few critical structural components at the a3b2 ACh binding pocket are responsible. Since RegIIA exhibits no change in activity at the a3b4 subtype, we anticipated that residue differences in the b2 subunit caused the 70-fold lower sensitivity at the human a3b2 subtype. Surprisingly, when any of the three nonhomologous residues in the rat b2 subunit are exchanged to the human counterpart, only modest loss in sensitivity to RegIIA is observed (Fig. 2D) . Conversely, a single exchange of residue Q198 in loop C of the rat a3 subunit can shift the IC 50 to values consistent with those of human a3b2 nAChRs (Fig. 2, C and D) .
Other mutations around loop A ([Q73G,V75A] and [D97V]) and loop C ([E187D]) in the rat a3 subunit do not cause any significant loss in activity (Fig. 2D and Table 1 ). Taken together the mutational analyses show that only a single residue in the ECD of the a3 subunit, located within the principal interface of the ACh binding domain, appears crucial for the ∼70-fold RegIIA potency differences at human and rat a3b2.
Interestingly, a-conotoxin RgIA's affinity for the rat a9a10 nAChR was previously reported to be about 100-fold higher than that for the human subtype. Similarly to our findings with RegIIA and a3b2, only a single residue difference in the a9 subunit (Thr56 to Ile) was responsible for this two orders of magnitude change in affinity, as shown by receptor mutagenesis (Azam and McIntosh, 2012) .
To understand the role of Q198P exchange in RegIIA species selectivity, we dissected the contribution of individual nAChR residues to RegIIA binding. MM-PBSA free-energy calculations reveal the importance of a3(1)-E195 (Fig. 4A) , which does not interact with RegIIA in ra3b2 (Fig. 4B ) but does interact with RegIIA-N11 and N12 for ha3b2 and ra3[Q198P]b2 (illustrated for ha3b2 in Fig. 4C ). We propose that, for a3[Q198P]b2 and ha3b2, the stronger interaction of a3-E195 with RegIIA-N12 causes steric hindrance, displacing RegIIA-N12 from its key contact with a3-Y197, the latter contact being present only in ra3b2 (Fig. 4B) . This leads to energetically less favorable peptide binding.
MM-PBSA calculations also revealed that for rat and human a3b4 subtypes, at which RegIIA is active, the contribution of a3(1)-E195 to (D)DG bind is not significantly different from that of ra3b2 (unlike ha3b2 and ra3[Q198P]b2). This further supports the notion that a3(1)-E195 is key to species-specific RegIIA inhibition. Therefore, although the a3 subunit is common between a3b2 and a3b4 subtypes, the complementary b subunit may help to change RegIIA's interactions with the a3 subunit, leading to species-dependent inhibition at a3b2 but not a3b4.
Interestingly, the reverse mutation at the homologous position in rat a4, P195Q, enhances a-conotoxin TxIA potency at a4b2. MD simulations of TxIA bound with an a4b2 dimer showed that P195 does not directly face the peptide binding site, but structurally changes loop C and prevents nearby residues from interacting with the peptide. Mutation a4[P195Q] improves flexibility of loop C, which increases the number of contacts between loop C residues (including a4-Y194) and TxIA (Beissner et al., 2012) . Surprisingly, we observed a severe loss in the affinity of the human a3b2 nAChR mutant ha3[P198Q]b2 for ACh. However, when coexpressed with rat b2 instead, as in the above paper, the hybrid ha3[P198Q]rb2 receptor produced robust ACh-evoked currents and revealed a left-shift of the concentration-response curve of RegIIA. This confirmed how important residue a3-Q198 is for determining receptor affinity for RegIIA.
The results reported by Beissner and coworkers (2012) are consistent with our proposed mechanism, in which contact between a3-Y197 (homologous to a4-Y194) and the residues RegIIA-N11 and -N12 plays a key role in the potency of RegIIA at ra3b2. At b2(2), S168 makes the most statistically significant positive (D)DG bind contribution to a3[Q198P]b2 and ha3b2 (Fig. 4D) . In ra3b2, b2-S168 does not form any close contact with RegIIA but does form an intrasubunit hydrogen bond with b2-D171. In turn, this forms a persistent salt bridge with the RegIIA-G1 N-terminus (Fig. 4E) . In contrast, at a3[Q198P]b2 and human a3b2, both interactions are absent (Fig. 4F) . We propose that, by stabilizing b2-D171 in a conformation that allows salt bridge contact with RegIIA-G1, the internal H-bond between b2-S168 and b2-D171 plays an indirect role in facilitating RegIIA activity at ra3b2.
MD simulations also reveal differences between the three receptors in the absence of RegIIA that may help to bias ra3b2 toward favorable binding with RegIIA. At ra3(1), in approximately 80% of the MD trajectories, the distance between the hydroxyl H of Y197 and side-chain Cd of E195 lies within 3.5 Å (shaded areas in Fig. 5A ), suggesting the existence of a persistent contact (Fig. 5B ). For ra3 [Q198P] (1), this contact exists only ∼40% of the time (Fig. 5, A and C) , whereas the ha3(1) lies inbetween at ∼70% (Fig. 5A ). This interaction locks Y197 into a specific conformation that may partly confer favorable binding of ra3b2 with RegIIA, compared with the two RegIIA-inactive receptors.
Similarly for ra3b2, at b2(2), the distance between the hydroxyl H of S168 and side-chain C« of D171 lies within 3.5 Å for ∼50% of the time (shaded areas in Fig. 5, D and E) . In contrast, for ra3[Q198]b2 and ha3b2, the contact time is ∼9% and 5%, respectively, indicating lack of a persistent contact (Fig. 5, D and F) . This trend is also present when RegIIA is bound (Fig.  4, D-F) . A persistent contact between S168 and D171 for RegIIAbound and apo ra3b2 supports how important this interaction is, in particular for maintenance of D171 in a position potentially enabling salt bridge formation with the N terminus of RegIIA.
We used MD simulation and alanine-scanning analysis to identify interactions between residue a3-Q198 and a-conotoxin AuIB at the rat a3b4 nAChR subtype (Grishin et al., 2013) . However, at a3b4, this residue is not the major determinant for AuIB potency. The main determinants for AuIB potency are on the b4 subunit (Grishin et al., 2013) . These findings indicate the a3 residue at position 198 does not appear to have the same Fig. 4 . MD simulations reveal key residues on a3b2 nAChRs and RegIIA for species-specific difference in sensitivity to the peptide. (A) Bar graph summarizing (D)DG bind between RegIIA and residue a3-E195 of human a3b2 and mutant ra3[Q198]b2 relative to rat a3b2. In the a3(+) subunit, a3-E195 exhibits a significantly more positive (D)DG bind at ra3[Q198]b2 and ha3b2 receptors (*p , 0.05). (B) Graphical representation of rat a3-E195 interaction with RegIIA. Rat a3 nAChR backbone is depicted in transparent blue ribbon form with residues of interest either as space-filling (ra3-Q198) or licorice models (ra3-E195, ra3Y197). The a-conotoxin RegIIA backbone is shown in a yellow ribbon representation and residues N11 and N12 highlighted in licorice form. Dashed lines indicate approximate distances between receptor and toxin side-chain atoms of interest. Atoms are color coded as: C, cyan; H, white; N, blue; and O, red. MD analysis reveals that at the a3(+) subunit in rat a3b2, RegIIA-N12 forms a H-bond with a3-Y197, whereas a3-E195 has less effect on peptide binding due to greater distance. (C) At human a3b2, the H-bond between a3-Y197 and RegIIA-N12 is disrupted and replaced by a H-bond between N12 and a3-E195. In addition, residue a3-E195 makes close contact with RegIIA-N11 potentially forming another H-bond. (D) Bar graph summarizing (D)DG bind between RegIIA and residue b2-S168. On the b2(2) subunit of human a3b2 and mutant ra3[Q198]b2 receptors, residue b2-S168 exhibits significantly increased (D)DG bind for RegIIA (*p , 0.05). (E) Graphical representation of rat b2-S168 interaction with RegIIA. Rat b2 nAChR backbone is depicted in transparent red ribbon form. RegIIA-G1 (N-terminal amine) forms a salt bridge with b2-D171, which in turn forms a H-bond with b2-S168. (F) Both interactions are absent with human a3b2. Error bars in (A) and (D) are calculated as S.E.M. over 10 independent simulations and two a3(+)b2(2) interfaces.
Species Difference of a-Conotoxin RegIIA Potency at nAChRs importance for binding a-conotoxins in a3b4 as it has in a3b2. Our experimental data with RegIIA, which lacks a major species-specific difference in sensitivity at a3b4, support this hypothesis. Furthermore, MD simulations indicate that, similar to AuIB, other residues specific for b4 within the agonist binding loops are more important for determining RegIIA's binding affinity for a3b4.
Recent studies of the molecular and structural basis for a-conotoxin BuIA and LvIA selectivity identified key residues on the b(2) interface of the b2 subunit that contribute to these toxins' activity and selectivity (Shiembob et al., 2006; Zhangsun et al., 2015) , confirming that each a-conotoxin requires specific structural determinants for effective receptor binding.
Our study provides novel pharmacological information about conformational differences at the a(1) interface of rat and human a3b2 subtypes, and how these differences affect activity of the competitive antagonist RegIIA. Furthermore, the synthetic peptide [N11A,N12A]RegIIA is, to our knowledge, the most selective pharmacological probe available that selectively inhibits the human a3b4 nAChR over the a3b2 subtype. Identifying the molecular basis for the different potencies of species-specific nAChR antagonists will facilitate the design and development of novel, potent and highly subtype-selective nAChR drugs. An in-depth understanding of the structural prerequisites for human nAChR-selective probes will also increase the success rates of drug candidates in clinical trials.
